Dr. Stephen Blacklow currently serves as an MPM Advisor. Stephen is the Gustavus Adolphus Pfeiffer Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and a member of the Department of Cancer Biology at the Dana Farber Cancer Institute.
Research by Stephen’s team has furthered the understanding of how cells can communicate with one another and cause each other to undergo downstream changes, which is an important mechanism in many cancers. His research on the Notch pathway has led to the development of new investigational therapies for hematologic malignancies such as T cell ALL.
Of his many other awards and professional affiliations, Stephen received the National Cancer Institute’s prestigious Outstanding Investigator Award in 2017 and was elected to the Association of American Physicians in 2018. Stephen also directed the MD-PhD Program in Basic and Translational Sciences at Harvard Medical School and has served on Advisory Committees for pre-clinical departments, graduate programs, and MD-PhD programs at several major research universities and institutions, including Stanford, the University of Pennsylvania, and the Memorial Sloan Kettering Cancer Center.
Stephen earned his M.D. and Ph.D. from Harvard University in 1991. He completed his residency in Clinical Pathology at Brigham and Women’s Hospital and conducted his postdoctoral research at the Whitehead Institute with Dr. Peter S. Kim.
Dr. William (Bill) C. Hahn currently serves as an Advisor to MPM and BioImpact Capital, an affiliate manager of MPM. Bill is a leading scientist and physician involved in biomedical research and in the care of cancer patients. He is currently Chief Research Strategy Officer and Chief, Division of Molecular and Cellular Oncology at Dana-Farber Cancer Institute and is also an Institute Member of the Broad Institute.
Bill’s numerous groundbreaking discoveries have informed the current molecular understanding of cancer and have defined the tools, technologies and experimental models used to discover and validate targeted cancer therapies. Widely recognized for his work, he was honored with the 2015 Richard and Hinda Rosenthal Award from AACR and the Ho-Am Prize in Medicine in 2010.
He serves as a medical oncologist and Professor at the Dana-Farber Cancer Institute and Harvard Medical School and is an Institute Member of the Broad Institute of MIT and Harvard. He is also the Chief Research Strategy Officer and the Chief of the Division of Molecular and Cellular Oncology in the Department of Medical Oncology at Dana-Farber Cancer Institute.
Of his many other awards and professional affiliations, Bill received the Wilson S. Stone Award from M.D. Anderson Cancer Center for outstanding research in cancer and the Howard Temin Award from the National Cancer Institute; he has also served as President of the American Society for Clinical Investigation and was elected to the Association of American Physicians.
Bill earned his M.D. and Ph.D. from Harvard Medical School and his B.A. from Harvard University. He completed clinical training in internal medicine at Massachusetts General Hospital and medical oncology at Dana-Farber and conducted his postdoctoral studies in the lab of Robert Weinberg at the Whitehead Institute for Biomedical Research.
Dr. David P. Ryan currently serves as an Advisor to both MPM and BioImpact Capital, an affiliate manager of MPM. David is Chief of Hematology/Oncology, Massachusetts General Hospital (MGH) Cancer Center, the Clinical Director of the MGH Cancer Center, and a Professor of Medicine, Harvard Medical School.
David undertook his hematology and oncology training at the combined MGH/Dana-Farber Cancer Institute in 1996 in Boston, MA. In 1998, he was appointed Clinical Assistant in Medicine at MGH, then Assistant in Medicine. The principal focus of his clinical research is the design and implementation of Phases I and II trials in gastrointestinal malignancies. Since 1998, he has been a member of both the Experimental Therapeutics Group and the Gastrointestinal Cancer Center where he has been the Clinical Director since 2003. In 2009, he became the Clinical Director of the MGH Cancer Center and in 2012, became Chief of the MGH Cancer Center. His clinical practice focuses exclusively on gastrointestinal oncology.
David graduated in medicine from Columbia College of Physicians and Surgeons, New York, NY in 1992 where he remained for his internship and medical residency. He is a member of the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO) and the New England Cancer Society. He has published over 50 articles in peer review journals, reviews, book chapters and editorials, and authored numerous abstracts.
Dr. H. Robert (Bob) Horvitz has been an Advisor to MPM since 2005 and has served as the Chairman of MPM’s Advisory Boards since 2007.
Having joined the Massachusetts Institute of Technology’s Department of Biology faculty in 1978, he was named the David H. Koch Professor of Biology in 2000. He was appointed a Member of the Koch Institute for Integrative Cancer Research in 2000 and a Member of the McGovern Institute for Brain Research in 2001. He is a member of the Board of Trustees of the Massachusetts General Hospital.
Bob received the 2002 Nobel Prize in Physiology or Medicine for discovering and characterizing genes that control programmed cell death (apoptosis), findings that have provided the basis for understanding many aspects of human biology and disease.
Bob is a member of the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and The Royal Society of London. He is a recipient of the Gairdner Foundation International Award, the Alfred P. Sloan, Jr. Prize from the General Motors Cancer Research Foundation and the Bristol-Myers Squibb Award for Distinguished Achievement in Neuroscience. He received a Ph.D. in Biology in 1974 from Harvard University and S.B. degrees in Mathematics and Economics from MIT in 1968.